Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691.
Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchal J, Peterson BA; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group. Smith SM, et al. Among authors: gockerman jp. Leuk Lymphoma. 2009 Oct;50(10):1606-17. doi: 10.1080/10428190903093807. Leuk Lymphoma. 2009. PMID: 19626540 Free PMC article. Clinical Trial.
Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA. Bartlett NL, et al. Among authors: gockerman jp. Cancer. 2001 Jul 15;92(2):207-17. doi: 10.1002/1097-0142(20010715)92:2<207::aid-cncr1311>3.0.co;2-d. Cancer. 2001. PMID: 11466671 Clinical Trial.
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.
Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, Gockerman JP, Garcia RA, Rizzieri DA. Shea TC, et al. Among authors: gockerman jp. Leuk Lymphoma. 2009 May;50(5):741-8. doi: 10.1080/10428190902853136. Leuk Lymphoma. 2009. PMID: 19358012 Clinical Trial.
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
Lanasa MC, Davis PH, Datto M, Li Z, Gockerman JP, Moore JO, DeCastro CM, Friedman DR, Diehl LF, Rehder C, Cook H, Daugherty FJ, Matta KM, Weinberg JB, Rizzieri D. Lanasa MC, et al. Among authors: gockerman jp. Leuk Lymphoma. 2012 Feb;53(2):218-24. doi: 10.3109/10428194.2011.610012. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21827374
Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
Brander D, Rizzieri D, Gockerman J, Diehl L, Shea TC, Decastro C, Moore JO, Beaven A. Brander D, et al. Leuk Lymphoma. 2013 Dec;54(12):2627-30. doi: 10.3109/10428194.2013.784969. Epub 2013 Apr 19. Leuk Lymphoma. 2013. PMID: 23488610 Free PMC article. Clinical Trial.
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Rao AV, Younis IR, Sand GJ, Spasojevic I, Adams DJ, Decastro CM, Gockerman JP, Peterson BL, Petros WP, Moore JO, Rizzieri DA. Rao AV, et al. Among authors: gockerman jp. Leuk Lymphoma. 2008 Aug;49(8):1523-9. doi: 10.1080/10428190802210700. Leuk Lymphoma. 2008. PMID: 18766965 Clinical Trial.
128 results